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MicroRNA-155 inﬂuences B-cell function through
PU.1 in rheumatoid arthritis
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MicroRNA-155 (miR-155) is an important regulator of B cells in mice. B cells have a critical
role in the pathogenesis of rheumatoid arthritis (RA). Here we show that miR-155 is highly
expressed in peripheral blood B cells from RA patients compared with healthy individuals,
particularly in the IgD-CD27- memory B-cell population in ACPAþ RA. MiR-155 is highly
expressed in RA B cells from patients with synovial tissue containing ectopic germinal centres
compared with diffuse synovial tissue. MiR-155 expression is associated reciprocally with
lower expression of PU.1 at B-cell level in the synovial compartment. Stimulation of healthy
donor B cells with CD40L, anti-IgM, IL-21, CpG, IFN-a, IL-6 or BAFF induces miR-155 and
decreases PU.1 expression. Finally, inhibition of endogenous miR-155 in B cells of RA patients
restores PU.1 and reduces production of antibodies. Our data suggest that miR-155 is an
important regulator of B-cell activation in RA.
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R
heumatoid arthritis (RA) is a chronic inﬂammatory
polyarthritis characterized by clinical and synovial hetero-
geneity1. Histological analysis of RA joints shows that
inﬂammatory cells within the synovial tissue can establish
microstructures resembling the follicular structures normally
residing in lymphoid organs. The presence of those structures is
correlated with compartmentalized accumulation of B and T cells
and with a speciﬁc cytokine pattern within the synovium2.
B-cell analysis suggests that these structures function as
germinal centres (GC) wherein antigen-activated B cells locally
differentiate into effector cells3. Moreover, aggregate units are
surrounded by anti-citrullinated peptide antibody (ACPA)-
producing plasma cells and probably contribute to autoimmune
disease progression via activation-induced cytidine deaminase3.
Several lines of evidence suggest an important role for speciﬁc
miRNAs in RA4,5. MicroRNA-155 (miR-155) has a crucial role in
the development of experimental arthritis6; previous studies show
that miR-155 mutant mice display defective B- and T-cell
immunity and abnormal function of antigen presenting cells7,8.
A reduced number of GC B cells are observed in miR-155
deﬁcient mice, whereas miR-155 overexpression has the opposite
phenotype8. Microarray analysis of B cells activated under
conditions that promote class switching to IgG1 suggests that
miR-155 regulates expression of many genes, a substantial
proportion of which are predicted to be direct targets of
miR-155. One of these is the transcription factor PU.1 that is
highly expressed in miR-155-deﬁcient B cells. PU.1 over-
expression in wild-type B cells results in reduced numbers of
antigen-speciﬁc IgG1-producing cells indicating that miR-155,
through the negative regulation of PU.1 has an important role in
antigen-driven B-cell maturation in mice9. However, the role of
miR-155 in B cells of RA patients has not been described. In
particular, understanding epigenetic regulatory mechanisms in
RA B cells could facilitate the development of new biomarkers or
therapeutic strategies to manage RA.
The aims of our study were therefore: (i) to assess the
expression of miR-155 in B cells of RA patients in multiple
biological compartments (PB, SF and synovial tissue, respec-
tively), (ii) to evaluate the possible association between miR-155
expression and B-cells activation features (deﬁned as ACPA
positivity and ectopic synovial GC frequency), (iii) to assess the
relationship between miR-155 and its target PU.1 in synovial
tissue and circulating B cells of RA patients and (iv) to investigate
the impact of miR-155 on RA B-cell function.
Results
Follicles are present in early and long-standing RA. Seventy-
four patients (60 RA and 14 OA respectively) underwent ultra-
sound guided synovial tissue biopsy. Demographic and clinical
characteristics of enrolled patients subgroups are summarized in
Table 1. RA patients were younger (55.9±13.9 years) and had
higher systemic inﬂammation (erythrocyte sedimentation rate
(ESR): 45.5±32.8mm/1st hour) compared to OA patients
(age: 64.0±7.3 years, P¼ 0.04 and ESR: 26.1±20.6mm/1st hour,
P¼ 0.02, Mann-Whitney U-test). OA patients were neither
ACPA positive nor exhibited synovial follicular structures
(Table 1). In contrast, 48.3% of RA patients exhibited synovial
follicular structures at synovial tissue biopsy. RA patients were
categorized according to disease duration as early RA (n¼ 27) or
long-standing RA (n¼ 33). ERA and LSRA patients show
signiﬁcantly higher CD20þ , CD3þ and CD68þ cells inﬁltration
within synovial tissue compared to OA patients (Fig. 1a-g), in the
lining and in the sublining areas. No difference in the frequency
of ectopic lymphoid structures within synovial tissue was
observed between ERA and LSRA patients as evaluated by CD21
staining (14(51.8%) of ERA had synovial follicular pattern versus
15(45.5%) of LSRA had synovial follicular pattern respectively;
P¼ 0.62, w2 test) (Fig. 1a) and (Table 1)). Moreover, we found
that CD20, CD3 and CD68 staining scores did not differ between
ERA and LSRA patients (Fig. 1a-g).
miR-155 is highly expressed in RA B cells. Next, we divided RA
patients according to seropositivity for ACPA but independent of
disease duration. ACPA-positive RA patients exhibited higher
frequency of follicular structures within synovial tissue compared
to ACPA-negative patients. Twenty-two (68.7%) ACPA-positive
RA patients had synovial follicular pattern versus 12 (49.0%)
ACPA-negative RA patients with a synovial follicular pattern
(P¼ 0.04). CD20þ cells were overrepresented in the sublining of
synovial tissue of ACPA-positive RA patients compared to
ACPA-negative patients (P¼ 0.01, Mann-Whitney U-test)
(Supplementary Fig. 1a,b). Among ACPA-positive RA patients
we found a direct correlation between ACPA plasma titre and
synovial aggregate grade via the histological evaluation [r¼ 0.382;
P¼ 0.01; 95%CI (0.12–0.61), Spearman Rank Correlation
coefﬁcient].
We next assessed miR-155 expression in B cells from patients
with different clinical features and from different tissue
compartments. MiR-155 is expressed at higher levels in RA
CD19þ cells (n¼ 24) compared to CD19þ cells isolated from
healthy controls (HC) (n¼ 9) (Po0.0001, Mann-Whitney U-test)
(Fig. 2a). Flow cytometric analysis (FACS) of CD19þ cells shows
a higher proportion of pre-switched memory (IgDþCD27þ )
(P¼ 0.02) and double negative memory B cells (IgDCD27 )
(P¼ 0.05, Mann-Whitney U-test) in RA compared to HC
(Fig. 2b). Stratiﬁcation of RA patients according to
ACPA positivity revealed that CD19þ cells isolated from PB of
ACPA positive show higher miR-155 expression than HC and
Table 1 | Demographical, clinical and immunological parameters of enrolled RA, PsA and OA patients (tissue phenotyping,
miR-155 expression in CD19þ and in tissues).
Parameters OA cohort (n¼ 14) PsA cohort (n¼5) RA cohort (n¼60) ERA (n¼27) LSRA (n¼33) p
Female, n (%) 10 (71.4) 3 (60.0) 47 (78.3) 20 (74.1) 27 (81.8) 0.47
Age, years (mean±s.d.) 64.0±7.3 56.8±11.4 55.9±13.9 51.2±13.2 59.5±13.6 0.61
Disease duration, months (mean±s.d.) 4.8±2.6 7.3±3.1 11.7±4.8 6.7±5.6 15.6±3.9 0.001
DAS28 (mean±s.d.)  4.7±0.9 4.9±1.2 5.0±1.3 4.81±1.12 0.89
ACPA positivity, n (%) 0 (0.0) 0 (0.0) 32 (53.3) 15 (55.6) 17 (51.5) 0.76
Follicular synovial pattern, n (%) 0 (0.0) 2 (40.0) 29 (48.3) 14 (51.8) 15 (45.5) 0.62
ESR, mm/1st hour(mean±s.d.) 26.1±20.6 42.7±23.8 45.5±32.8 50.3±35.7 41.5±30.1 0.06
CRP, mg/dL(mean±s.d.) 9.0±11.0 19.8±21.6 20.3±23.5 19.6±18.0 20.9±27.6 0.79
ACPA, anti-citrullinated peptides antibodies; CRP, C-reactive protein; DAS, disease activity score; ERA, early RA; ESR, erythrocyte sedimentation rate; LSRA, long-standing RA; OA, osteoarthritis; PsA,
psoriatic arthritis; RA, rheumatoid arthritis.P¼ ERA versus LSRA patients. Bold: statistically signiﬁcant. P values were evaluated by Mann-Whitney U-test or w2 test as appropriate.
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ACPA-negative RA patients (P¼ 0.002, Mann-Whitney U-test).
Moreover, CD19þ cells isolated from peripheral blood (PB) of
ACPA-positive early RA patients show higher expression of miR-
155 then ACPA-positive LSRA patients (P¼ 0.002, Mann-
Whitney U-test) (Fig. 2c). Furthermore, CD19þ cells isolated
from synovial ﬂuid (SF) exhibit signiﬁcantly higher miR-155
expression than CD19þ cells isolated from paired PB of RA
patients (P¼ 0.04, Wilcoxon-test) (Fig. 2d). FACS analysis of
CD19þ cells subpopulations in paired PB-SF samples of RA
patients shows that SF compartment is characterized by
signiﬁcantly lower proportion of naive B cells (IgDþCD27-)
(Po0.001) and higher proportion of post-switched memory
(IgD-CD27þ ) (P¼ 0.002, Mann-Whitney U-test) and double
negative memory B cells (IgD-CD27-) (P¼ 0.01, Mann-Whitney
U-test) compared to the PB compartment (Supplementary Fig. 2).
MiR-155 expression in SF-derived CD19þ cells directly
correlates with double negative memory B cells percentages
(IgD-CD27-) [r¼ 0.627; P¼ 0.05; 95%CI (0.17–0.95); Spearman
Rank Correlation coefﬁcient] suggesting a tight biological link
between miR-155 and activated and maturation status of B cells
in synovial compartment.
To dissect formally the expression pattern of miR-155 in B-cell
subpopulations, we investigated miR-155 expression in sorted HC
and ACPAþ RA PB CD19þ cells and observed that double
negative memory RA B cells (IgD-CD27-) show the highest
expression of miR-155 compared to other B-cell subpopulations
(Fig. 2e), suggesting that an increased level of miR-155 in RA PB
and SF CD19þ cells is likely due to an increased number of
double negative memory B cells.
To dissect whether high levels of miR-155 in RA B cells are
related to chronic inﬂammation and/or to B-cells maturation
status, we analysed miR-155 expression in PB-derived B cells
from autoantibody negative Psoriatic Arthritis (PsA) patients
naı¨ve to treatment with active systemic disease (DAS28 4.7±0.9)
and compared to RA and HC. PsA patients have a lower
proportion of memory CD19þ IgD-CD27- cells (P¼ 0.03,
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Figure 1 | CD20, CD3, CD68 and CD21 in synovial tissue from early and long-standing RA. (a) Representative pictures of CD68 (red)/CD21 (DAB,
brown) and CD20 (DAB, brown)/CD3 (red) in synovial tissue from early, long-standing RA and OA patients (original magniﬁcation,  20); (b-c) CD20
staining score for lining and sublining areas of synovial tissue from early (n¼ 27) and long-standing RA (n¼ 33) patients; * CD20 staining in early RA
versus OA (n¼ 14) patients; ** CD20 staining in long-standing RA versus OA patients; (d–e) CD3 staining score for lining and sublining areas in synovial
tissue from early (n¼ 27) and long-standing RA (n¼ 33) patients; * CD3 staining in early RA versus OA patients; ** CD3 staining in long-standing RA
versus OA (n¼ 14) patients; (f-g) CD68 staining score for lining and sublining areas in synovial tissue from early (n¼ 27) and long-standing RA (n¼ 33)
patients; * CD68 staining in early RA versus OA (n¼ 14) patients; ** CD68 staining in long-standing RA versus OA patients. Data are mean±s.d.,
*Pr0.05, **Pr0.01; Mann-Whitney U-test; ns¼ not signiﬁcant.
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Mann-Whitney U-test) compared to RA (Supplementary Fig. 3).
PB-derived B cells of PsA patients show miR-155 expression
higher than HC (P¼ 0.001, Mann-Whitney U-test) and compar-
able to ACPA-negative RA patients (P¼ 0.25,
Mann-Whitney U-test); but signiﬁcantly lower than ACPAþ
RA patients (Fig. 2f). These data suggest that expression of
miR-155 in B cells can be associated with chronic inﬂammation;
however, in RA patients is strongly related to ACPA positivity.
miR-155 is abundantly expressed in B cells of RA synovium. To
assess miR-155 expression in inﬁltrating B cells within the
synovial tissue, we performed miR-155 ﬂuorescent in situ
hybridization on synovial tissues of RA patients. This
demonstrated that synovial B cells abundantly express miR-155
(Fig. 3a-c). MiR-155 is preferentially overexpressed in synovial
tissue of RA patients with follicular pattern, compared to those
with diffuse pattern (Fig. 3d). This ﬁnding was conﬁrmed on
tissue lysates by qPCR. Synovial tissue of RA patients with
a follicular pattern shows 3.96±4.19 fold higher expression of
miR-155 compared to synovial tissue of RA patients with a diffuse
pattern (P¼ 0.001, Mann-Whitney U-test) and 20.54±14.52 fold
more than OA (Po0.0001, Mann-Whitney U-test) (Fig. 3e).
In addition, we found that RA patients with a synovial
follicular pattern are characterized by CD19þ cells showing
higher expression of miR-155 in PB and SF compartment
compared to RA patients with diffuse pattern (P¼ 0.03 and
P¼ 0.05 respectively, both calculated using Mann-Whitney
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Figure 2 | miR-155 expression in CD19þ cells from RA, PsA and HC. (a) miR-155 expression in peripheral blood (PB) CD19þ cells isolated from RA
(n¼ 24) and HC (n¼ 9); *Po0.0001 RA versus HC; Mann-Whitney U-test; (b) FACS analysis of B-cell subpopulations in PB of RA (n¼ 24) and HC
(n¼9); *P¼0.02 and **P¼0.05 RA versus HC; Mann-Whitney U-test; (c) miR-155 expression in CD19þ cells isolated from PB of RA patients based on
disease duration and ACPA positivity; * P¼0.032 ACPA- ERA versus HC; **P¼0.0004 ACPAþ ERA versus HC and ***P¼0.002 ACPAþ ERA versus
ACPA- ERA; ^P¼0.04 ACPA- LSRA versus HC; ^^P¼0.0002 ACPAþ LSRA versus HC and ^^^P¼0.002 ACPAþ LSRA versus ACPA- LSRA; y P¼0.04
ACPAþ ERA versus ACPAþ LSRA; Data are shown as mean±s.d., 25–75 percentiles; Mann-Whitney U-test; (d) miR-155 expression in paired samples
(n¼ 10) of CD19þ cells isolated from PB and synovial ﬂuid (SF) of RA patients; *P¼0.04 SF CD19þ cells versus PB CD19þ cells; Wilcoxon test; (e) miR-
155 expression in sorted B-cell subpopulations from PB of RA patients (n¼6) and HC (n¼6) in three independent experiments. *P¼0.02; Mann-Whitney
U-test; (f) miR-155 expression in PB-derived CD19þ cells of RA and PsA patients; * P¼0.032 ACPA- ERA versus HC; **P¼0.0004 ACPAþ ERA versus
HC and ***P¼0.002 ACPAþ ERA versus ACPA- ERA; ^P¼ PsA versus HC; ^^P¼0.25 ACPA- ERA versus PsA; yP¼0.01 ACPAþ ERA versus PsA; data are
shown as mean±s.d., 25–75 percentiles; Mann-Whitney U-test.
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U-test) (Fig. 3f). These observations suggest that miR-155 might
be an important regulator of RA B-cell activation associated with
autoantibody production.
miR-155 is inducible in CD19þ cells. To dissect which
mediators regulate miR-155 expression in human B cells,
PB-derived CD19þ cells from healthy donors were stimulated
with interleukin-21 (IL-21), CpG, CD40L, anti-immunoglobulin
M (anti-IgM), IFN-a, IL-6 and B-cell activating factor
(BAFF), which are known as activation and survival factors of B
cells10–16 (n¼ 5). We found that CD40L (2 mg/ml) and anti-IgM
(10 mg/ml) are able to induce miR-155 expression in CD19þ cells
already after 24 h of stimulation (22.03±30.91 and 6.70±2.69
fold increase Po0.05, respectively, Mann-Whitney U-test) and
sustain the increase at later time points (48 and 72 h). While
IL-21 (50 ng/ml), CpG (1 mg/ml) and IFN-a (400 IU/ml) induce
miR-155 expression in CD19þ cells after 48 h of stimulation
(2.12±0.85 fold with IL-21; 6.12±3.10 fold with CpG and
6.58±10.77 fold with IFN-alpha compared to baseline RPMI;
Po0.05 respectively, all calculated using Mann-Whitney U-test)
(Fig. 4). This increase persisted through 72 h. IL-6 and BAFF,
which are regulators of B-cell activation15,16 and are present at
high levels in SF compared to PB regardless of histological pattern
in synovial tissues in RA patients (Supplementary Fig. 4) are also
able to signiﬁcantly increase miR-155 expression in CD19þ cells
after 48 and 72 h stimulation (1.5±0.34 and 3.70±2.21 fold
change after 48 and 72 h BAFF stimulation and 2.10±1.37; and
3.90±2.50 fold change after 48 and 72 h IL-6 stimulation)
(Fig. 4). These data suggest that a wide range of inﬂammatory
mediators and B-cell activators increase expression of miR-155 in
B cells with the strongest impact mediated via maturation factors.
Thus the cytokine and cell-rich RA synovial compartment is
likely responsible for perpetuation of high levels of miR-155 in
synovial B cells; and miR-155 may integrate at molecular levels
distinct signals leading to B-cell activation.
PU.1 is decreased in RA B cells within synovial compartment.
Among miR-155 target genes, PU.1 was selected and evaluated in
detail because it is crucial for early B-cell commitment and a
negative regulator of B-cell maturation9,17–19. PU.1 is similarly
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expressed in PB B cells from healthy controls, RA patients
(P¼ 0.89, Mann-Whitney U-test) and PsA patients (P¼ 0.81,
Mann-Whitney U-test) (Fig. 5). Analysis of PU.1 expression in
paired PB and SF samples of RA patients revealed that SF-derived
CD19þ cells have lower PU.1 levels than PB-derived CD19þ
cells (P¼ 0.002, Wilcoxon test), consistent with a higher
expression of its negative regulator miR-155 in the synovial
compartment (Fig. 5b). Stratiﬁcation of RA patients according to
ACPA positivity revealed that SF-derived CD19þ cells of
ACPAþ RA patients show signiﬁcantly lower PU.1 expression
compared to ACPA- patients (Fig. 5a). An inverse correlation
between miR-155 and PU.1 expression in SF-derived B cells
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coefﬁcient; (d) PU.1 expression in PB CD19þ cells isolated from HC (n¼ 5) after in vitro stimulation with CD40L (2mg/ml), IL-21 (50 ng/ml), anti-IgM
(10mg/ml), CpG (1mg/ml), Interferon alpha (400 IU/ml), IL-6 (30 ng/ml) and BAFF (20ng/ml) for 24–72 h; *Po0.05 CD40L, anti-IgM, IL-21, CpG,
IFN-alpha, BAFF or IL-6 versus Baseline RPMI; data are shown as mean±s.d.; Mann-Whitney U-test.
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[r¼  0.65; P¼ 0.04; 95%CI ( 0.38 to  0.88) Spearman Rank
Correlation coefﬁcient] (Fig. 5c) further supports the presence
of an active interaction between miR-155 and its target in
RA B cells. Since negative regulation of PU.1 by miR-155 has
been experimentally validated20, we next investigated PU.1
expression in B cell after stimulation with factors triggering
miR-155 expression. We found that miR-155 is inducible by
several factors including CD40L, anti-IgM, CpG, IL-21, IFN
alpha, BAFF and IL-6. Conversely we found that PU.1 gene
expression is signiﬁcantly decreased after 48 and 72 h stimulation
of CD19þ cells with CD40L, anti-IgM, CpG, IL-21, IL-6 and
BAFF (Fig. 5d). In particular, PU.1 levels inversely correlate with
miR-155 expression in healthy B cells after 72 h stimulation
with CD40L [r¼  0.99; P¼ 0.0001; 95%CI ( 0.98 to  1.00),
Spearman Rank Correlation coefﬁcient], CpG [r¼  0.97;
P¼ 0.026; 95%CI ( 0.85 to  1.00), Spearman Rank Corre-
lation coefﬁcient] and BAFF [r¼  0.99; P¼ 0.01; 95%CI
( 0.66 to  1.00), Spearman Rank Correlation coefﬁcient]
respectively.
Immunohistochemical analysis demonstrated the presence of
PU.1 in the synovial tissue with both a diffuse (Fig. 6a,b) and a
follicular pattern (Fig. 6d,f). To quantitatively assess PU.1
expression in synovial tissue we performed RT-PCR on synovial
tissue lysates, which revealed that RA patients with follicular
synovitis have signiﬁcantly less expression of PU.1 compared to
RA patients with diffuse synovitis (P¼ 0.02, Mann-Whitney
U-test) (Supplementary Fig. 5). Moreover, we found signiﬁcant
inverse correlation between miR-155 and PU.1 expression in
synovial tissue lysates in RA patients with follicular synovitis
[r¼  0.76; P¼ 0.01; 95%CI ( 0.58 – to  0.93), Spearman
Rank Correlation coefﬁcient]. To visualize PU.1 expression
speciﬁcally in synovial B cells we performed double immuno-
ﬂuorescence for PU.1 and CD20 in synovial tissue biopsies of RA
patients with follicular synovitis. Commensurate with qPCR data,
only a few CD20þ cells within the ectopic lymphoid structures
were positive for PU.1 (Fig. 6e).
All together these data support the notion that a miR-155-PU1
axis might be involved in RA B-cell activation.
miR-155 inhibition in RA B cells reduces antibody synthesis.
To functionally evaluate the role of miR-155 in RA B-cell
activation, the expression of its target genes and production of
IgG were evaluated in RA PB B cells transfected with a control or
miR-155 inhibitor. Patient clinical data and B-cell transfection
efﬁciency, which was above 60%, are shown in Supplementary
Table 1a-b and Supplementary Fig. 6. RA B cells (n¼ 6) trans-
fected with anti-miR-155 show a signiﬁcant increase of PU.1
expression (Po0.05, Wilcoxon test) compared to RA B cells
treated with control inhibitor at 48 h time point (Fig. 7). There
were no signiﬁcant changes in the expression of other B-cell-
speciﬁc transcription factors (IRF4, PRDM1 and PAX5), which
were previously reported to be under direct or indirect control of
miR-1559,21,22 (Fig. 7a). These data suggest that PU.1 is regulated
by miR-155 in RA B cells and that inhibition of miR-155 could
impact the antibody production. To test the latter possibility, PB
CD19þ cells from ACPAþ RA patients (n¼ 5) were transfected
with miR-155 or control inhibitor and stimulated with anti-IgM,
CD40L, IL-21 and BAFF or left unstimulated for 7 days.
Stimulation strongly increases total IgG production by RA B
cells (Fig. 7b) and miR-155 inhibition leads to a substantial
decrease in antibody production compared to control inhibitor
treated cells (Fig. 7b). These data suggest that miR-155 in RA B
cells is a key post-transcriptional regulator of antibody
production.
Discussion
RA is an autoimmune disease that affects nearly 1% of the
population and can lead to loss of function, disability and
increased mortality. To date, long lasting, usually drug-main-
tained disease remission can be achieved in about 40–50% of
cases. Thus there is considerable unmet need to fully understand
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Figure 6 | PU.1 expression in synovial tissue and synovial CD20þ cells of RA patients. (a–d) PU.1 Immunohistochemical staining (DAB) in synovial
tissue of RA patients. (a) Representative PU.1 staining (Brown-DAB) in synovial tissue with diffuse pattern; (b) Representative PU.1 staining (Brown-DAB)
in mononuclear cells in synovial lining of synovial tissue with diffuse pattern; (c,e) CD20 (DAB) and CD3 (RED) staining (original magniﬁcation  20) and
(d,f) PU.1 (DAB) staining in lymphocyte synovial follicules (original magniﬁcation  20); (g) Representative immunoﬂuorescence staining for PU.1
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the disease process in order to improve either use of available
therapeutics or elaboration of novel targets. In RA, immunolo-
gical dysregulation exempliﬁed by, for example, ACPA serological
positivity and serum cytokine/chemokine proﬁles, reﬂects loss of
immunological tolerance to self-antigen, and can be detected
several years before the clinical onset of arthritis23. This places
B cells in the centre of pathogenesis of RA. B-cell depletion
therapy is effective in a proportion of RA patients24. A critical
stage of effector B-cell development is deﬁned by GC formation.
During the GC reaction, B cells undergo somatic hypermutation
of their immunoglobulin variable regions and class-switch
recombination. B cells that have acquired the ability to express
high afﬁnity immunoglobulins are then positively selected and
further differentiate into ﬁnal effectors of the humoural immune
response, that is, memory B cells and plasma cells contributing to
immune response by antibody release, antigen presentation and
by releasing a wide range of cytokine and chemokines25.
Synovial inﬁltration by inﬂammatory cells occurs with different
degrees in RA: from diffuse to simple cellular aggregates, to real
pseudo-follicular structures resembling GC (lymphoid neogen-
esis). Despite active research there are still controversial data on
this issue3,26. Because of synovial inﬁltrates variability, it is
mandatory to distinguish between lymphoid aggregation
and lymphoid neogenesis27. It has been proposed that synovial
tissue with ectopic lymphoid neogenesis characterizes a distinct
physiopathologic subtype of RA patients and that its presence
is related to synovial inﬂammation in early RA patients and
can change over time during the disease course28. Our study
suggests that synovial follicular structures are present during
an early disease phase and can be detected with a similar
frequency in RA patients responding and not responding to
methotrexate treatment, consistent with prior studies27. The
biological activity of the synovial aggregate structures is still
undeﬁned—contradictory data on their role in the promotion of
autoimmunity, chronic inﬂammation and driving the production
of pathogenetic autoantibodies exist: Humby et al demonstrated
that synovial follicular units in RA express activation-induced
cytidine deaminase and are surrounded by ACPA-producing
plasma-cells3, whereas Cantaert et al demonstrated that ectopic
lymphoid neogenesis is not directly associated with the local
production of ACPA and RF in RA joints29. Our ﬁndings support
those of Humby et al since we found a signiﬁcantly higher
incidence of synovial aggregate pattern and signiﬁcantly higher
percentages of resident CD20þ , CD68þ and CD3þ cells in
ACPA-positive patients compared to ACPA-negative ones.
Several lines of evidence suggest an important role for speciﬁc
miRNAs in B-cell function8,20,30–33. MiRNA deregulation was
found in several B-cells-mediated diseases. In mouse models,
miR-155 has been demonstrated to affect regulation of the GC
response through modulation of cytokine production4 and
optimal antibody response8,20,30–33. Moreover, miR-155
overexpression is associated with aggressive forms of diffuse
large B-cell lymphomas34. We have previously shown that
miR-155 has a crucial role in the development of experimental
arthritis6. MiR-155 / mice are resistant to collagen-induced
arthritis associated with lower levels of anti-collagen antibodies
suggesting a central role of miR-155 in loss of tolerance and in
promoting B-cell-driven autoimmune processes6. Herein, we
provide for the ﬁrst time evidence of the overexpression of
miR-155 in B cells of RA patients in the PB and in the synovial
compartment. In particular, we found that the expression of
miR-155 in RA B cells is already increased and peaks in early
phases of the disease; mainly in double negative (IgD-/CD27-)
memory B cells. This population was described previously to be
increased in autoimmune diseases, including SLE and RA35,36
and to be important for IgGþ plasmablast generation37. The
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association between miR-155 expression in B cells and
auto-antibody production is suggested by the signiﬁcant higher
expression of miR-155 in B cells isolated from ACPA-positive RA
patients compared to ACPA-negative ones, particularly in the
early phases of the disease and in patients with follicular synovitis.
These data are commensurate with in vitro data showing that
maturation of B cells towards antibody-producing cells (anti-IgM,
CD40L stimulation) had the most signiﬁcant impact on miR-155
expression in B cells. Inﬂammatory mediators, including IL-6,
BAFF and IL-21 also increased miR-155 expression suggesting
that the overall inﬂammatory milieu contributes to miR-155
expression in B cells. This was supported by the presence of
elevated levels of miR-155 in B cells of PsA patients with high
disease activity. However, these levels were comparable to those
observed in ACPA-negative RA patients, implicating that
maturation of B cells towards antibody-producing cells is the
key factor in miR-155 expression in RA.
RA synovium likely comprises a niche in which expanded
autoreactive B-cells and autoreactive plasma cells can reside38.
B-cell memory is supported by plasma cells, responsible for
antibodies production, and memory B cells, representing
precursors able to replace plasma cells through antigen-
dependent and independent mechanisms39. This maturation
cascade of B cells is regulated by miR-155 in physiologic
condition with a progressive upregulation of miR-155 from
naı¨ve to memory committed B cells4. We found that most of the
resident synovial CD20þ cells in synovial follicules were miR-155
positive. Among the possible molecular mechanisms by which
miR-155 can inﬂuence B-cell activation, we investigated the
ets-family transcriptional regulator PU.1. Vigorito et al. provided
strong evidence that mRNA encoding PU.1 is a miR-155 target20.
PU.1 mRNA is elevated in miR-155-deﬁcient mouse B cells and
miR-155 directly targets PU.1 mRNA via a predicted miR-155-
binding site in the 30 untranslated region. Moreover, they showed
that forced expression of PU.1 in cultured wild-type mouse
primary B cells recapitulates the miR-155-deﬁcient defect in IgG1
production. It is known that PU.1 is important for early B-cell
commitment and is downregulated during the maturation of B
cells17–19. The levels of PU.1 are high in GC B cells but are
reduced upon plasmacytic differentiation40. In our study we
assessed for the ﬁrst time the expression of PU.1 in B cells derived
from multiple biological compartments in RA patients ﬁnding
that SF-derived CD19þ cells from RA patients show lower
expression of PU.1 compared to healthy controls, consistently
with miR-155 overexpression. Lu et al demonstrated that PU.1 is
a negative regulator of Ig secretion in animal models9. In line with
this, our study revealed that SF-derived B cells of RA patients
show lower expression of PU.1 in ACPA-positive compared to
ACPA-negative RA patients and a low number of PU.1 positive
cells among resident CD20þ cells within synovial follicular
structures in RA patients. The functional analysis of miR-155 in
RA B cells revealed that inhibition of endogenous miR-155 in
these cells led to the restoration of PU.1 expression and inhibited
B-cell receptor (BCR) crosslinking induced antibody production.
In conclusion, our study suggests that RA B-cell antibody
production is controlled by the miR-155-PU1 pathway. Since
miR-155 has been previously demonstrated to be a regulator
of myeloid cell activity6 and of T cells41, we propose that an
inhibitor of miR-155 could be used to simultaneously treat both
myeloid and lymphoid synovial phenotypes1, increasing the current
response rate of RA patients (Fig. 8a-c). This is predicated however
on ﬁnding sufﬁciently safe modalities for miR-155 inhibition.
Materials and methods
Patient characteristics. Sixty consecutive patients fulﬁlling the American College
of Rheumatology 2010 revised criteria for RA42 were enrolled in the study at the
Division of Rheumatology, Fondazione Policlinico Universitario A. Gemelli,
Catholic University of the Sacred Heart in Rome. As comparison groups we
included in the study patients (n¼ 14) with osteoarthritis (OA) and healthy control
subjects (n¼ 9) [7(78%) female; 54.7±8.6 years-old] (HC). RA patients were
divided into early (ERA) (n¼ 27) and long standing (LSRA) (n¼ 33) based on the
disease duration (more or less than 1 year). All ERA patients were naı¨ve to any
pharmacological treatment whereas all LSRA were taking stable dose of
Methotrexate (mean dose: 12.9±6.1mg/week). PsA patients43 (n¼ 5) with active
disease (DAS28 4.7±0.9) due to peripheral joints arthritis without spine
involvement, and naı¨ve to treatment were enrolled as a comparison group. Clinical
and laboratory evaluations included the Disease Activity Score (DAS28), the
number of tender and swollen joints at 28 sites, the ESR and C-reactive protein.
All PB samples were tested for IgM and IgA Rheumatoid Factor (RF) isotypes
(Orgentec Diagnostika, Dundee, UK) and ACPA antibodies (Diastat, Axis-Shield
Diagnostics, Ltd., Dundee, UK). The study protocol was approved by the local
Ethic Committee of the Catholic University of the Sacred Heart and by the West of
Scotland Research Ethical Committee (11/S0704/7). All subjects provided signed
informed consent.
Immunohistochemistry on synovial tissues. All enrolled patients underwent
ultrasound guided synovial tissue biopsy of the knee. All patients underwent
ultrasound evaluation of the knee using an ultrasound machine with a multi-
frequency linear transducer (MyLab Twice, Esaote). Using the ultrasound view, the
best point of entrance for the needle was identiﬁed on the lateral margin of the
suprapatellar recess. Each patient was provided with a face-mask and cap and the
whole procedure was undertaken under sterile conditions. Skin disinfection was
done with iodine solution (performed twice, starting from the point of needle
entrance up to 25 cm proximally and distally). Arthrocentesis of the knee joint was
performed using the lateral suprapatellar access if joint effusion was present. The
skin, subcutaneous tissue and joint capsule was anaesthetised with 10ml lidocaine
2%. Next, a 14G needle (Precisa 1410-HS Hospital Service Spa, Italy) was inserted
into the joint. Regions of synovial hypertrophy were identiﬁed under grey-scale
guidance44 to ensure sampling of representative synovial tissue. All the synovial
tissue specimens obtained (at least eight pieces for each analysis) were placed on a
nonwoven wet gauze for collection44. Once collected, synovial tissue specimens
were ﬁxed in 10% neutral-buffered formalin and embedded in parafﬁn for
histology or stored in Qiazol for RNA isolation. Brieﬂy, parafﬁn-embedded ST
specimens were sectioned at 3–4 mm. Firstly, sections were stained for Hematoxylin
and Eosin as follows: sections were deparafﬁnized in xylene and rehydrated in a
graded ethanol series. Then, they were stained in hematoxylin and counterstained
in Eosin/Phloxine. Finally, sections were dehydrated, cleared in xylene and
mounted with Bio Mount (Bio-Optica). Other sections were stained with IgG2a
mouse anti-human monoclonal antibody for CD68 (clone 514H12; antibody at
6.7mg/ml) or IgG1 mouse anti-human monoclonal antibody for CD20 (clone L26;
at 1.2mg/ml) or IgG1 mouse anti-human monoclonal antibody for CD3 (clone LN
10; at 1.0mg/ml),or IgG2a mouse anti-human monoclonal antibody for CD21
(clone 2G9; at 0.34mg/ml; all from Leica Biosystem, Newcastle, UK), or IgG rabbit
monoclonal anti-human for PU.1 (#2266; dilution 1/100, Cell Signalling
Technology) by immunostainer BOND MAX III (Leica, Newcastle, UK).
Double immunohistochemical staining for CD21/CD68 and CD20/CD3,
or single immunohistochemical staining for PU.1 was performed as follows:
3-mm-thick sections were prepared from formalin-ﬁxed parafﬁn-embedded
tissue blocks and were dried in a 60 C oven for 30min. The sections were placed
in a Bond Max Automated Immunohistochemistry Vision Biosystem (Leica
Microsystems GmbH, Wetzlar, Germany) according to the following protocol:
ﬁrstly, tissues were deparafﬁnized and pre-treated with the Epitope Retrieval
Solution 1 (CITRATE buffer) or Solution 2 (EDTA-buffer) at 98 C for 10min
according to the manufacturer’s instructions. After washing, peroxidase blocking
was carried out for 10min using the Bond Polymer Reﬁne Detection Kit DC9800
(Leica Microsystems GmbH). Tissues were again washed and then incubated with
the primary antibody for 30min. Subsequently, tissues were incubated with
polymer for 10min and developed with DAB-Chromogen or RED-Chromogen and
ﬁnally counterstained with hematoxylin45.
Slides were examined using a light microscope (Leica DM 2000). RA and OA
tissues were classiﬁed as diffuse or follicular based on the immunostaining of
CD68, CD21, CD20 and CD3 positive cells46. RA and OA tissues were evaluated
using a numerical score based on the number of positive cells in the lining and
sublining areas of the section (three different ﬁelds in each section), with a score of
0 indicating no positive cells; 1 indicatingo10% positive cells; 2 indicating 10–50%
positive cells; and 3 indicating 450% positive cells6. —Six to eight samples were
collected and evaluated for each patient, to reduce the sampling error44.
In situ hybridization on synovial tissues. After deparafﬁnization, sections were
treated with proteinase-K (15 mg/ml) at 37 C for 10min. Hybridization with
5 nmol Locked Nucleic Acid 50 and 30 digoxigenin (DIG)-labelled control scramble
(GTGTAACACGTCTATACGCCCA) or miR-155–speciﬁc (TATCACGATTA
GCATTAA) probes (both from Exiqon) was performed at 50 C for 1 h. After
hybridization, sections were washed in 5 SSC at 50 C for 5min, in 1 SSC at
50 C for two washings of 5min each, in 0.2 SSC at 50 C for two washings of
5min each, and in 0.2 SSC at RT for 5min. Next, sections were blocked with DIG
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Wash and Blocking buffer (Roche) in a humidifying chamber at room temperature
(RT) for 15min. Slides then were incubated with alkaline phosphatase-conjugated
sheep anti-DIG antibody (1:800; Roche) in blocking solution supplemented with
2% sheep serum for 1 h at RT. Sections were incubated with nitro-blue tetrazolium
and 5-bromo-4-chloro-30-indolyphosphate solution (Roche) at 30 C for 2 h. To
stop the reaction, slides were washed twice for 5min with buffer containing 50mM
Tris-HCl, 150mM NaCl and 10mM KCl. Nuclear counterstaining was performed
using Nuclear Fast Red (Vector).
Some sections were incubated with ﬂuorescein-conjugated anti-DIG antibody
(Roche) followed by incubation with monoclonal mouse anti-human CD20 antibody
(at 1mg/ml; DakoCytomation) at 4 C overnight. On the next day, sections were
incubated with biotinylated horse anti-mouse IgG (Hþ L; Vector) for 30min at RT
followed by incubation with Texas Red Avidin D (Vector) at RT for 30min. Negative
control slides were prepared in the same manner using mouse nonspeciﬁc IgG1
(DakoCytomation). The sections were analysed using a ﬂuorescent imaging
microscope (LSM 510 Meta confocal microscope (Zeiss, Cambridge, UK)) and the
images captured using Zeiss imaging acquisition software. Signal from controls was
subtracted from the signal of miR-155/CD20 staining.
Fluorescent immunohistochemistry on synovial tissue. Double immuno-
ﬂuorescence staining was performed on formalin-ﬁxed RA synovial tissues with a
primary antibody against CD20 (clone L26 mouse anti-human monoclonal
antibody, at 1.2mg/ml, Leica Biosystem, Newcastle, UK) and anti-PU.1 (rabbit
monoclonal anti-human PU.1, #2266; dilution 1/100, Cell Signalling Technology)
at 37 C for 1 h. Sections then were rinsed and incubated with the appropriate
secondary conjugated antibodies (Fluorescein isothiocyanate (FITC) conjugated
goat anti-mouse IgG H&L, #ab6785, (Abcam) (dilution 1/1000) and Tetra-
methylrhodamine isothiocyanante (TRITC) conjugated goat anti-rabbit IgG H&L,
#ab6718, Abcam (dilution 1/1000)) at RT for 1 h. Antigen retrieval was performed
by microwaving in a citric acid-pH 9.2. To minimize nonspeciﬁc antibody binding,
slides were pre-incubated with phosphate-buffered saline 10% bovine serum
albumin (BSA) for 30min. Slides were mounted in medium containing DAPI
(H-1200; Vector) and were scanned on an APERIO ﬂuorescent microscope
(Leica Biosystems).
FACS of B cells in PB and SF. Fresh PB or SF samples were processed within a few
hours after sample collection. One hundred microlitres of whole PB in EDTA,
or 5 105 mononuclear cells derived from SF (separated by Ficoll-Hipaque
(Cederlane, Ontario, Canada) density gradient centrifugation) in 100 ml of
phosphate-buffered saline were ﬁrst incubated in the dark at RT for 20min with
anti-human antibodies speciﬁc for CD45 (APC-A750) (clone J33) (dilution 1/25),
CD19 (APC-700) (clone J3-119) (dilution 1/25), CD38 (PC5 or APC) (clone
LS198-4-3) (dilution 1/25), CD27 (PC7) (clone 1A4CD27) (dilution 1/25) and
FITC-conjugated IgD (clone IA6-2) (dilution 1/25) (all by Beckman Coulter,
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Marseille France). After staining, the cells were ﬁxed, washed and erythrocytes were
lysed. Samples were immediately analysed on optimally compensated 8 color
Navios ﬂow-cytometer and data were analysed with Kaluza software (Beckman
Coulter, Marseille, France). Lymphocytes were gated on the basis of forward and
side-scatter light properties (conﬁrmed by CD45 staining) and at least 10,000
CD19þ cells were analysed. B-cell subsets were evaluated by the expression of
surface B-cell markers according to IgD/CD27 classiﬁcation47.
miR-155 expression in CD19þ cells by qPCR. Peripheral blood (HC, RA, PsA)
and synovial ﬂuid mononuclear cells (PBMCs/SFMCs) were isolated by density
gradient centrifugation on histopaque. CD19þ cells were then isolated from the
mononuclear preparation using CD19 MACS MicroBeads (Miltenyi Biotech), and
total RNA from the puriﬁed CD19þ cells was isolated using the miRNeasy kit
(Qiagen). The CD19þ cells purity was assessed by FACS analysis (mean±s.d.;
97.0±0.7). The miScript Reverse Transcription Kit (Qiagen) was used for cDNA
preparation. Expression of miR-155 and U1/U6 (housekeeping controls) was
evaluated using the SYBR Green method using human miR-155 (MS00003605)
and U1 (MS00013986) or U6 (MS00033740) speciﬁc primers (Qiagen).
miR-155 expression in RA B-cell subsets sorted from PB. CD19þ B cells were
enriched from PBMCs from RA patients (n¼ 6) (Supplementary Table 1c) using
CD19 microbeads and Auto-MACS separator according to the manufacturer’s
protocol (Miltenyi Biotec). Puriﬁed CD19þ cells were then stained with a
viability marker (Fixable Viability Dye eFluors 780, eBioscience) for 20min
followed by staining with ﬂuorochrome-labelled antibodies: FITC anti-human
CD27 (clone M-T27) (#356404, dilution 1/20, Biolegend), PE/Cy7 anti-human
CD38 (clone HB-7) (#356608, dilution 1/20, Biolegend), APC/H7 mouse
anti-human IgD (clone IA6-2) (#561305, dilution 1/20, BD Bioscience) and
PerCP-Cy5.5 mouse anti-human IgM (clone G20-127) (#561285, dilution 1/20, BD
Bioscience). Using recommended isotype controls the speciﬁcity of the staining was
assured. Cells were incubated with antibodies or isotypes for 30min at 4 C.
Puriﬁed B-cell subsets were sorted using FACS Aria III using a 75mm nozzle and
the expression of miR-155 was evaluated as described above.
PU.1 expression in CD19þ cells from RA patients by qPCR. CD19þ cells were
isolated from paired PB and SF samples from 10 RA patients. An iScriptTM cDNA
Synthesis Kit (Bio Rad Laboratories, Hercules, CA) was used for cDNA prepara-
tion. A FastStart Universal Probe Master (Roche Diagnostics, Germany) was used
for qPCR using the following primers/probes: human PU.1 (100053625) and
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH, 100015432) both from
Roche Diagnostics, Germany.
Plasma/synovial ﬂuid IL-6 and BAFF. IL-6 and BAFF in plasma and SF
(if available) of RA subjects were measured by ELISA kit following the instructions
of the manufacturer (R&D Systems, UK). The sensitivity of the test was 0.70 pg/ml
for IL-6 and 2.68 pg/ml for BAFF respectively.
miR-155 and PU.1 expression in stimulated CD19þ cells. CD19þ cells were
puriﬁed from PBMCs of ﬁve healthy control subjects [49.2±12.1 years old, 4(80%)
female] using CD19 MACS MicroBeads (Miltenyi Biotech). CD19þ cells were
suspended at 5 105 in 0.5ml of complete culture medium (RPMI with 10% FCS,
100U/ml penicillin and 100 mg/ml streptomycin) and were incubated in the wells
of a 48-well culture plate with or without CD40L (2 mg/ml; Enzo Life Sciences),
IL-21 (50 ng/ml; R&D), anti-IgM (10 mg/ml; Jackson ImmunoResearch), CpG
(1mg/ml; InvivoGen), IFN-alpha (400 IU/ml; pbl assay science), IL-6 (30 ng/ml;
R&D) or BAFF (20 ng/ml; R&D) for 24, 48 or 72 h at 37 C in 5% CO2. After
stimulation, CD19þ cells were collected and the RNA was harvested, and the
miR-155 and PU.1 expression was assessed by qPCR as described above
Transcription factors expression in RA B cells. Puriﬁed CD19þ cells from
RA patients (n¼ 6; Supplementary Table 1a) were transfected with either
hsa-miR-155-5p inhibitor (miR-155I) or control inhibitor (CI) using the Neon
Transfection System with protocol number 2 (Voltage¼ 2000, Pulse number¼ 2).
Transfected cells were seeded in 24-well plates at a concentration of 2 106 cells in
1ml of complete medium (RPMI 1640 medium; Invitrogen) supplemented with
10% FCS, 100U/ml penicillin and 100 mg/ml streptomycin L-Glutamine (2mM) in
the presence of IL-6 (30 ng/ml) and BAFF (20 ng/ml). Cells were incubated at 37 C
in 5% CO2 for 24 and 48 h respectively. Cell viability and transfection efﬁciency
were evaluated with Fixable Viability Dye eFluor 780 and Dy547 labelled control
inhibitor respectively (Supplementary Fig. 6a,b). The total RNA was reverse
transcribed into cDNA using the High Capacity cDNA reverse transcription kit
(Applied Biosystems, UK). Quantitative PCR was performed on triplicate samples
using the ABI 7900HT Fast Real Time PCR System (Applied Biosystems, UK) with
TaQman probe and primers; HS00277134_m1 PAX5, HS00153357_m1PRDM1,
HS02786711_m1SPI1 and SYBR Green primers: IRF4 FW 50- ACC GGC AGA
TGT CCA TGA G- 30 and IRF4 Rev: 50-GTG GCA TCA TGT AGT TGT GAA
CCT -30 . The expression of target genes was normalized to the endogenous
control 18S.
IgG production by CD19þ cells upon miR-155 manipulation. PB CD19þ cells
from ACPA-positive RA patients (n¼ 5, Supplementary Table 1B; Supplementary
Fig. 6a,b) were transfected with miR-155 inhibitor or control inhibitor as described
above and cultured at a density of 2 104 cells/well in IMDM supplemented with
10% FCS, penicillin/streptomycin (100U/ml) and 2mM Glutamax in 96-wells ﬂat
bottom plates. Transfected cell were either stimulated with plate bound human
CD40 ligand (2 mg/ml) and anti-IgM (5 mg/ml) in the presence of BAFF
(100 ng/ml), IL21 (50 ng/ml) or left unstimulated in media supplemented in
survival factors: IL-6 (30 ng/ml) and BAFF (20 ng/ml) for 7 days as described by
Kerkman et al48. Each condition was performed in 14-10 replicates. Standard
ELISA was used to assess the level of total IgG in culture supernatants.
Statistical analysis. Statistical analysis was performed using SPSS 20.0 (SPSS,
Chicago, IL) and Prism software (Graph-Pad, San Diego, CA). Categorical
and quantitative variables were described as frequencies, percentage and
mean±standard deviation (s.d.). Data on demographic and clinical features were
compared between patients using the non-parametric Mann-Whitney U test or w2
test, as appropriate. The Wilcoxon test was used to compare cytokines levels
between matched PB and SF. For the semi-quantitative determination of the
expression of human miR-155 and the control U1 in CD19þ cells, DCt values were
generated after subtraction from the gene of interest (miR-155) Ct value of controls
(U1). The DDCt values were obtained by normalizing the DCts with the mean DCt
of healthy control group. For the semi-quantitative determination of the expression
of human PU.1 and the control GAPDH, DCt values were generated, after
subtraction from the gene of interest (PU.1) Ct value of controls (GAPDH). The
DDCt values were obtained by normalizing the DCts with the mean DCt of healthy
control group or the mean value of RA patients with diffuse synovitis. Relative
quantitative values for the expression of miR-155 in B cell subsets and transcription
factors in cultured B cells were calculated as 2^DCt, after subtraction from the
gene of interest (miR-155/transcription factors) Ct value of controls (U6 or 18S).
Spearman’s rank correlation test was used for correlation in all analyses. A P value
o0.05 was considered statistically signiﬁcant.
Data availability. The data that support the ﬁndings of the study are available
from the corresponding author upon request.
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